Biodexa Pharmaceticals
Yahoo Finance • 13 days ago
Biodexa Pharmaceuticals GAAP EPS of £0.00
* Biodexa Pharmaceuticals press release [https://seekingalpha.com/pr/20230561-interim-results-for-the-six-months-ended-june-30-2025] (NASDAQ:BDRX [https://seekingalpha.com/symbol/BDRX]): 1H GAAP EPS of £0.00. MORE ON BIODEXA PHARMACEUTIC... Full story
Yahoo Finance • 13 days ago
Interim results for the six months ended June 30, 2025
September 12, 2025 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Interim results for the six months ended June 30, 2025 Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipe... Full story
Yahoo Finance • last month
Biodexa Announces Enrolment of First Patients into Pivotal Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)
August 18, 2025 Biodexa Announces Enrolment of First Patients into Pivotal Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) Opportunity to be First Mover in $7.3Bn Addressable Market Biodexa Pharmaceuticals PLC (“Biodexa”... Full story
- NVDA
Mentioned:
Yahoo Finance • 2 months ago
U.S. stocks lower at close of trade; Dow Jones Industrial Average down 0.74%
Investing.com – U.S. stocks were lower after the close on Thursday, as losses in the Healthcare, Consumer Goods and Financials sectors led shares lower. At the close in NYSE, the Dow Jones Industrial Average declined 0.74%, while the S&P... Full story
Yahoo Finance • 2 months ago
ADR Ratio Change Effective
July 31, 2025 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) ADR Ratio Change Effective ADSs Outstanding Post Ratio Change Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a p... Full story
Yahoo Finance • 2 months ago
Biodexa Pharmaceuticals to implement 1:10 ADR ratio change
NEW YORK - Biodexa Pharmaceuticals PLC (NASDAQ:BDRX), whose stock has declined nearly 76% over the past six months according to InvestingPro data, announced Tuesday it will change the ratio of its American Depositary Receipts (ADRs) effect... Full story
Yahoo Finance • 2 months ago
ADR Ratio Change
July 15, 2025 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) ADR Ratio Change Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), an acquisition-focused clinical stage biopharmaceutical company developing a pipeline of innovative pro... Full story
Yahoo Finance • 3 months ago
Results of Annual General Meeting
June 27, 2023 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Results of Annual General Meeting Biodexa Pharmaceuticals PLC (NASDAQ: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative product... Full story
Yahoo Finance • 3 months ago
Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP)
June 25, 2025 Biodexa Announces Activation of First Clinical Study Site for Phase 3 Serenta Trial in Familial Adenomatous Polyposis (FAP) Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), (Nasdaq: BDRX), a clinical stage biopharm... Full story
Yahoo Finance • 3 months ago
Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP)
June 23, 2025 Biodexa Unveils "Serenta" as the Name of its Upcoming Phase 3 Study In Familial Adenomatous Polyposis (FAP) Biodexa Pharmaceuticals PLC (“Biodexa” or “the Company”), (Nasdaq: BDRX), a clinical stage biopharmaceutical compan... Full story
Yahoo Finance • 3 months ago
Biodexa Pharmaceuticals changes share nominal value
Cardiff-based Biodexa Pharmaceuticals PLC has announced a significant change in the nominal value of its ordinary shares. The pharmaceutical company, known for its specialization in pharmaceutical preparations, has reduced the nominal valu... Full story
Yahoo Finance • 3 months ago
Result of General Meeting
June 11, 2025 Biodexa Pharmaceuticals PLC Result of General Meeting Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (NASDAQ: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the... Full story
Yahoo Finance • 4 months ago
Shareholder Update
May 30, 2025 Biodexa Pharmaceuticals PLC Shareholder Update Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatme... Full story
Yahoo Finance • 4 months ago
Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Notice of General Meeting
May 22, 2025 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company”) Notice of General Meeting Biodexa Pharmaceuticals PLC, (Nasdaq: BDRX), a clinical stage biopharmaceutical company developing a pipeline of innovative products for th... Full story
Yahoo Finance • 4 months ago
Biodexa Announces Award of Additional $3.0M Grant from CPRIT to Support Registrational eRapa Phase 3 Program in FAP Brings Total CPRIT Grant Funding for eRapa Phase 3 Program to $20.0M
May 22, 2025 Biodexa Announces Award of Additional $3.0M Grant from CPRIT to Support Registrational eRapa Phase 3 Program in FAP Brings Total CPRIT Grant Funding for eRapa Phase 3 Program to $20.0M Biodexa Pharmaceuticals PLC (“Biodexa”... Full story
Yahoo Finance • 5 months ago
Preliminary Results for the Year Ended 31 December 2024
April 11, 2025 Biodexa Pharmaceuticals PLC (“Biodexa” or the “Company” or, together with its subsidiaries, the “Group”) Preliminary Results for the Year Ended 31 December 2024 Biodexa Pharmaceuticals PLC (Nasdaq: BDRX), an acquisition-... Full story
Yahoo Finance • 7 months ago
Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP
March 10, 2025 Biodexa Announces Successful Outcome of a Type C Meeting with FDA Regarding the Phase 3 Program for eRapa in FAP Clears the way to finalize Phase 3 protocol and recruit sites for U.S. Phase 3 substantially funded by $17.0... Full story
Yahoo Finance • 7 months ago
Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP
March 6, 2025 Biodexa Announces Appointment of Precision for Medicine LLC as CRO for European Component of Phase 3 Study of eRapa in FAP Biodexa is finalizing plans to initiate an international Phase 3 registrational study of eRapa in... Full story
Yahoo Finance • 7 months ago
Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (“eRapa”) and Use
February 24, 2025 Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (“eRapa”) and Use Biodexa plans to initiate a Phase 3 registrational study of eRapa in Familial Adenomatous Polyposis (FAP... Full story
